Coronary Artery Disease (CAD) Clinical Trial
Official title:
A Phase I Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of XTR003 in Healthy Chinese Volunteers
18F-FDG PET imaging is now considered the most effective method used in the clinical evaluation of viable myocardium. However, the need for fasting or glucose and insulin loading in the 18F-FDG PET protocol makes it unfavorable for a certain group of patients (i.e., insulin-resistance and diabetic patients). XTR003 is a fatty acid analog used for PET imaging, developed at the Beijing Anzhen Hospital affiliated to Sinotau Pharmaceutical Group. XTR003 is a promising fatty acid analog and perhaps have a potential clinical utility in the evaluation of viable myocardium. This phase I study investigated the safety, biodistribution, radiation dosimetry and Pharmacokinetics of XTR003 in 10 Chinese normal healthy volunteers both male and female between the ages of 18-40.
XTR003 is a PET imaging radiopharmaceutical agent used to trace myocardial fatty acid metabolism. XTR003 is a modified fatty acid that enters the myocytes and passes through mitochondrial membrane by the same process as the natural existing fatty acids and then undergoes partial β-oxidation before being trapped in the mitochondria. In preclinical study XTR003 showed high myocardial uptake and retention [1]. This is a phase I study, the study will be open-label, nonrandomised, single-arm, single-center clinical study. Subjects will receive single dose of XTR003. Safety, biodistribution, radiation dosimetry and Pharmacokinetics was investigated. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05292079 -
CAPTURER PMCF Study ( rEPIC04D )
|
||
| Recruiting |
NCT05292092 -
Essential Pro PMCF Study ( rEPIC04E )
|
||
| Recruiting |
NCT05292014 -
ANGIOLITE PMCF Study ( rEPIC04F )
|
||
| Recruiting |
NCT05292118 -
Navitian PMCF Study ( rEPIC04C )
|
||
| Completed |
NCT05292105 -
NC Xperience PMCF Study( rEPIC04B)
|
||
| Terminated |
NCT01443754 -
Hybrid Revascularisation by Combined Coronary Artery Bypass Graft (CABG) and PCI in Multivessel Coronary Disease
|
N/A | |
| Completed |
NCT01435031 -
EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions
|
N/A | |
| Completed |
NCT00783302 -
Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical Care
|
N/A | |
| Completed |
NCT00543400 -
Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)
|
Phase 2 | |
| Completed |
NCT05516784 -
Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile
|
Phase 4 | |
| Completed |
NCT02873052 -
MyoVista Measurements in Patients With Atherosclerosis and CAD
|
||
| Terminated |
NCT02984891 -
Optical Coherence Tomography (OCT) Intravascular Ultrasound (IVUS) Dual Imaging
|
||
| Completed |
NCT05292144 -
Xperience Pro PMCF Study
|
||
| Completed |
NCT02554292 -
Post Market Surveillance of SeQuent Please Neo With Scoring Balloon
|
||
| Active, not recruiting |
NCT06052319 -
A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population
|
||
| Completed |
NCT00265525 -
Evaluation of a Web-based Intervention to Promote Physical Activity in Patients With Heart Disease.
|
Phase 3 | |
| Completed |
NCT03570697 -
Imaging of Coronary Plaques in Participants Treated With Evolocumab
|
Phase 3 | |
| Terminated |
NCT05508893 -
Screening for Coronary Artery Disease USing Primary Evaluation With Coronary CTA in Aviation Medicine (SUSPECT)
|
N/A | |
| Completed |
NCT02341664 -
Patient and Provider Assessment of Lipid Management Registry
|
||
| Completed |
NCT02098772 -
Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol
|
Phase 3 |